Goldenwell Biotech, Inc.
GWLL
$0.77
-$0.13-14.44%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 200.00% | 0.00% | 62,200.00% | 7,360.00% | -114.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 200.00% | 0.00% | 62,200.00% | 7,360.00% | -114.29% |
| Cost of Revenue | -- | -- | -150.00% | -125.00% | -100.00% |
| Gross Profit | -- | -- | 20,900.00% | 37,500.00% | 100.00% |
| SG&A Expenses | -12.60% | -3.05% | 11.85% | -8.04% | 15.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 123.25% | 141.09% | 11.57% | -8.39% | 15.13% |
| Operating Income | -123.42% | -141.29% | 41.53% | 36.47% | -15.56% |
| Income Before Tax | -101.22% | -128.42% | 36.84% | 31.52% | -20.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.22% | -128.42% | 36.84% | 31.52% | -20.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.22% | -128.42% | 36.84% | 31.52% | -20.97% |
| EBIT | -123.42% | -141.29% | 41.53% | 36.47% | -15.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -92.86% | -123.08% | 25.00% | 28.57% | -16.67% |
| Normalized Basic EPS | -125.00% | -125.00% | 28.57% | 37.50% | -14.29% |
| EPS Diluted | -92.86% | -123.08% | 25.00% | 28.57% | -16.67% |
| Normalized Diluted EPS | -125.00% | -125.00% | 28.57% | 37.50% | -14.29% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |